drugset
drugset / Trial / NCT05594875

A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

NCT05594875 ↗

Phase 1 Completed 9 enrolled Atridia Pty Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of SHR-1921.

Timeline

Start
2022-12-01
Primary completion
2024-04-24
Completion
2024-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1921 Unknown — —

Indications

neoplasm